John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
Medtronic Inc .’s experimental spinal fusion device Amplify didn’t work as well after five years as it did in two-year tests previously reported by the company, according to U.S. regulators weighing its approval for sale.
Jon Corzine, former chief executive of bankrupt futures brokerage MF Global Holdings Ltd., has said he never ordered any misuse of customer funds to help his firm stay afloat as it dealt with margin calls on bad bets.
Jon Corzine, the former head of MF Global Holdings Ltd., masterminded a scheme to inflate earnings that led to the eighth-biggest bankruptcy in U.S. history, according to an updated lawsuit filed by a trustee for the failed futures broker.
Medtronic Inc. Chief Executive Officer William A. Hawkins , 56, will retire next April, ending a three-year tenure that analysts said was marked by disappointing sales from the medical-device maker and a declining share price.
Edwards Lifesciences Corp. accepted restrictions on its Sapien heart valve that may cut U.S. sales $100 million in 2015 in exchange for guarantees Medicare will pay for its use in patients too sick for chest-opening surgery.